Retrospective review of male breast cancer patients: Analysis of tamoxifen-related side-effects

Annals of Oncology

Volumn 23, Issue 6, 2012, Pages 1471-1474

  Pemmaraju, N ^a   Munsell, M F ^a   Hortobagyi, G N ^a   Giordano, S H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Male breast cancer; Tamoxifen; Toxic effects

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAMOXIFEN;

ADULT; AGED; ARTICLE; BLURRED VISION; BONE PAIN; BREAST CANCER; CANCER STAGING; CATARACT; COGNITIVE DEFECT; DEPRESSION; DRUG WITHDRAWAL; EYE DISEASE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; INSOMNIA; LEG CRAMP; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL CONCENTRATION; MOOD CHANGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEXUAL DYSFUNCTION; SIDE EFFECT; THROMBOEMBOLISM; VISUAL ACUITY; WEIGHT GAIN;

EID: 84861752357     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr459     Document Type: Article

References (11)

1. Korde LA, Zujewski JA, Kamin L et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 2010; 28: 2114-2122.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Nahleh ZA, Srikantiah R, Safa M et al. Male breast cancer in the veterans affairs population: a comparative analysis. Cancer 2007; 109: 1471-1477.
4. Giordano SH, Cohen DS, Buzdar AU et al. Breast carcinoma in men: a population-based study. Cancer 2004; 101: 51-57.
5. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002; 137: 678-687.
6. Anelli TF, Anelli A, Tran KN et al. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 1994; 74: 74-77.
7. Visram H, Kanji F, Dent SF. Endocrine therapy for male breast cancer: rates of toxicity and adherence. Curr Oncol 2010; 17: 17-21.
8. Hershman DL, Kushi LH, Shao T et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010; 28: 4120-4128.
9. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 2007; 109: 832-839.
10. Dezentje VO, van Blijderveen NJ, Gelderblom H et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 2010; 28: 2423-2429.
11. Smith MR, Morton RA, Barnette KG et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 2010; 184: 1316-1321.